
Description
An early stage biotechnology company aiming to develop mutation agnostic therapies for Inherited Retinal Disease.
Team Members
Robert Millman
CEO
An early stage biotechnology company aiming to develop mutation agnostic therapies for Inherited Retinal Disease.